Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

Documenti analoghi

• Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
  di: Kumar, Vivek, et al.
  Pubblicazione: (2017)
• Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
  di: Raju Vaddepally, et al.
  Pubblicazione: (2022-03-01)
• Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
  di: Albandar, Heidar J., et al.
  Pubblicazione: (2021)
• Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies
  di: Zhang, Lei, et al.
  Pubblicazione: (2020)
• Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
  di: A Daban, et al.
  Pubblicazione: (2023-12-01)